Copenhagen, Denmark-based Traitomic has raised a €20 million ($22 million) Series A round for its gene-screening technology originally spun out from Danish brewing giant Carlsberg.
Sofinnova Partners led the round with participation from The Export and Investment Fund of Denmark (EIFO), Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures.
The company will use the funding to expand internationally, starting with the US and Australia.
Traitomic’s FIND-IT platform was first developed at the Carlsberg Research Laboratory to discover new traits in plants and microbes without editing an organism’s DNA. The platform identifies specific genetic variants in conventionally bred populations—for example, a gene linked to sugar content in tomatoes. That individual variant then becomes the starting material for the customer’s own breeding program or production strain.
Because these variations aren’t the result of genetic engineering or gene editing, the traits can be sold as conventional products, enabling Traitomic customers to avoid the regulatory hurdles that GM organisms, and some gene-edited ones, face in many markets.
Applications range from changing the flavor or nutritional makeup of a food and extending produce shelf life to making crops more drought-tolerant and improving the enzymes and microbial strains used in industrial biotech.
Cofounder and CEO Gustav Hambraeus says most trait-development approaches are tied to a specific type of organism, such as crops. Traitomic’s isn’t.
“We can develop traits very, very fast, and we are not bound by specific organisms,” he says. “We can do this in microbes. We can do this in plants. Over time, this has helped us generate quite a few traits.”
To date, the company has delivered 116 traits to 47 customers across 32 organisms. Those customers work in plant breeding and seed, food supply chain and precision nutrition, and biosolutions and industrial biotech.
‘No excuses anymore’
Hambraeus stresses that Traitomic’s traits are “market-ready.” Customers can commercialize them without regulatory delay, and they’re developed directly in the germplasm or strains that customers already sell.
“There are no excuses anymore for not doing trait development,” he says. “Don’t talk about regulatory hurdles. We can do this in any crop, and we can put it on the market in a completely conventional way.”
The real test, he adds, is whether those traits now reach consumers. “For the next five or six years, [the question is]: do we actually see these traits being implemented in the market? Are they actually commercialized?”
Towards commercial scale
Hambraeus says the raise is “all about commercial scaling and really getting out there.”
Traitomic has had a small presence in the US and Australia for the last couple of years. It now plans to grow in both markets, including hiring locally.
The funding will also let the company “take more risk with customers,” branching into new areas such as algae and mushrooms. Hambraeus says it will also work more closely with customers throughout projects.
“In this space, even though you have a good idea, it is difficult to convert it into a trait, then actually develop that trait, and then see that the phenotype is where you can get something,” says Hambraeus. “There are risks in many different steps here, and we can help the customer a little bit further on that journey.”

